Patient perspectives on pharmacogenomic (PGx) testing for antidepressant prescribing in primary care: a qualitative description study.
Genetic testing
Major depressive disorder
Patient perspectives
Pharmacogenomics
Primary care
Qualitative research
Journal
Journal of community genetics
ISSN: 1868-310X
Titre abrégé: J Community Genet
Pays: Germany
ID NLM: 101551501
Informations de publication
Date de publication:
08 Apr 2024
08 Apr 2024
Historique:
received:
20
01
2024
accepted:
28
03
2024
medline:
8
4
2024
pubmed:
8
4
2024
entrez:
8
4
2024
Statut:
aheadofprint
Résumé
Many patients with major depressive disorder (MDD) try multiple antidepressants before finding one that works well and is tolerable. Pharmacogenomic (PGx) testing was developed to facilitate more efficacious prescribing. This technology has not been robustly implemented clinically. Patient perspectives are critical to policy decisions, but the views of patients with MDD about the use of PGx testing to guide antidepressant prescribing have not been extensively examined, particularly in publicly funded healthcare systems. The purpose of this qualitative description study was to produce actionable patient perspectives evidence to inform future technology assessment of PGx testing. We conducted semi-structured interviews with 21 adults with MDD for which antidepressants were indicated in Ontario, Canada, and used the Ontario Decision Determinants Framework to conduct an unconstrained deductive content analysis. Patients expressed views about the overall clinical benefit of PGx testing in depression care, preferences for deployment of testing, perspectives on ethical considerations, opinions about equity and patient care, and beliefs regarding the feasibility of adopting PGx testing into the healthcare system. They also worried about the possibility of conflicts of interest between PGx test manufacturers and pharmaceutical companies. This study provides policymakers with patient priorities to facilitate the development of patient-centred policies. It highlights that formal adoption of PGx testing into the healthcare system requires a focus on equity of access and health outcomes.
Identifiants
pubmed: 38587601
doi: 10.1007/s12687-024-00705-y
pii: 10.1007/s12687-024-00705-y
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : CIHR
ID : Vanier Canada Graduate Scholarship
Pays : Canada
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Aboelbaha S, Zolezzi M, Elewa H (2021) Effect of pharmacogenetic-based decision support tools in improving depression outcomes: A systematic review. Neuropsychiatr Dis Treat 17:2397–2419. https://doi.org/10.2147/ndt.S312966
doi: 10.2147/ndt.S312966
pubmed: 34321882
pmcid: 8312313
Al Maruf A, Fan M, Arnold PD, Muller DJ, Aitchison KJ, Bousman CA (2020) Pharmacogenetic testing options relevant to psychiatry in Canada. Can J Psychiatry 65(8):521–530. https://doi.org/10.1177/0706743720904820
doi: 10.1177/0706743720904820
Allen JD, Pittenger AL, Bishop JR (2022) A scoping review of attitudes and experiences with pharmacogenomic testing among patients and the general public: Implications for patient counseling. J Pers Med 12(3). https://doi.org/10.3390/jpm12030425
Bagautdinova D, Lteif C, Eddy E, Terrell J, Fisher CL, Duarte JD (2022) Patients’ perspectives of factors that influence pharmacogenetic testing uptake: Enhancing patient counseling and results dissemination. Journal of Personalized Medicine 12(12): 2046. https://www.mdpi.com/2075-4426/12/12/2046
Bright D, Worley M, Porter BL (2021) Patient perceptions of pharmacogenomic testing in the community pharmacy setting. Res Social Adm Pharm 17(4):744–749. https://doi.org/10.1016/j.sapharm.2020.06.022
doi: 10.1016/j.sapharm.2020.06.022
pubmed: 32741696
Brown LC, Stanton JD, Bharthi K, Maruf AA, Müller DJ, Bousman CA (2022) Pharmacogenomic testing and depressive symptom remission: A systematic review and meta-analysis of prospective. Controlled Clinical Trials Clin Pharmacol Ther 112(6):1303–1317. https://doi.org/10.1002/cpt.2748
doi: 10.1002/cpt.2748
pubmed: 36111494
Burgess R, Cernat A, Little L, Vanstone M (2020) Implementing publicly funded noninvasive prenatal testing for fetal aneuploidy in Ontario, Canada: Clinician Experiences With a Disruptive Technology. Qual Health Res 30(12):1941–1952. https://doi.org/10.1177/1049732320945303
doi: 10.1177/1049732320945303
pubmed: 32741258
CADTH (2020) Pharmacogenomic testing for medication selection: A rapid qualitative review. https://www.cadth.ca/sites/default/files/rr/2020/RC1246%20PxGx%20Qualitative%20FINAL.pdf . Accessed Jan 2024
CADTH (2021) Pharmacogenomic testing in depression: a 2021 update. Available from: https://www.cadth.ca/sites/default/files/pdf/htis/2022/RC1403%20RxGx%20testing%20depression%20update%20Final.pdf . Accessed Jan 2024
CADTH (2023) An overview of pharmacogenomic testing for psychiatric disorders. https://www.cadth.ca/sites/default/files/pdf/htis/2023/EH0115%20Pharmacogenomic%20Testing%20for%20Psychiatric%20Disorders.pdf . Accessed Jan 2024
CANMAT (2016) CANMAT 2016 clinical guidelines for the management of adults with major depressive disorder. Canadian J Psych 61(9). https://doi.org/10.1177/0706743716660034
Clinical Pharmacogenetics Implementation Consortium (CPIC) (2023) Genes-drugs. https://cpicpgx.org/genes-drugs/ . Accessed 30 Mar 2024
Elo S, Kyngäs H (2008) The qualitative content analysis process. J Adv Nursing 62(1):107–115. https://doi.org/10.1111/j.1365-2648.2007.04569.x
doi: 10.1111/j.1365-2648.2007.04569.x
Fabbri C, Zohar J, Serretti A (2018) Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials. Prog Neuropsychopharmacol Biol Psychiatry 86:36–44. https://doi.org/10.1016/j.pnpbp.2018.05.007
doi: 10.1016/j.pnpbp.2018.05.007
pubmed: 29777729
Frigon MP, Blackburn ME, Dubois-Bouchard C, Gagnon AL, Tardif S, Tremblay K (2019) Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients. Pharmacogenomics 20(8):589–598. https://doi.org/10.2217/pgs-2019-0004
doi: 10.2217/pgs-2019-0004
pubmed: 31190623
Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, ... Lohr KN (2011) Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder. Ann Intern Med 155(11): 772–785. https://doi.org/10.7326/0003-4819-155-11-201112060-00009
Ghanbarian S, Wong GWK, Bunka M, Edwards L, Cressman S, Conte T, ... Bryan S (2023) Cost-effectiveness of pharmacogenomic-guided treatment for major depression. Cmaj 195(44): E1499-e1508. https://doi.org/10.1503/cmaj.221785
Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, ... Dechairo B (2019) Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res 111:59–67. https://doi.org/10.1016/j.jpsychires.2019.01.003
Grosse SD, Khoury MJ (2006) What is the clinical utility of genetic testing? Genet Med 8(7):448–450. https://doi.org/10.1097/01.gim.0000227935.26763.c6
doi: 10.1097/01.gim.0000227935.26763.c6
pubmed: 16845278
Hayes Inc (2016) Pharmacogenomic testing for selected conditions: a health technology assessment prepared for the Washington State Healthcare Authority. https://www.hca.wa.gov/assets/program/pharmacogenomics-final-rpt-20161209.pdf . Accessed Jan 2024
Hayward J, McDermott J, Qureshi N, Newman W (2021) Pharmacogenomic testing to support prescribing in primary care: a structured review of implementation models. Pharmacogenomics 22(12):761–776. https://doi.org/10.2217/pgs-2021-0032
doi: 10.2217/pgs-2021-0032
pubmed: 34467776
pmcid: 8438972
Hendricks-Sturrup RM, Lu CY (2019) Direct-to-consumer genetic testing data privacy: Key concerns and recommendations based on consumer perspectives. J Pers Med 9(2). https://doi.org/10.3390/jpm9020025
Hennink M, Kaiser BN (2022) Sample sizes for saturation in qualitative research: A systematic review of empirical tests. Soc Sci Med 292:114523. https://doi.org/10.1016/j.socscimed.2021.114523
doi: 10.1016/j.socscimed.2021.114523
pubmed: 34785096
Herbert D, Neves-Pereira M, Baidya R, Cheema S, Groleau S, Shahmirian A, ... Kennedy JL (2018) Genetic testing as a supporting tool in prescribing psychiatric medication: Design and protocol of the IMPACT study. J Psychiatr Res 96:265–272. https://doi.org/10.1016/j.jpsychires.2017.09.002
Kim RB (2019) Precision medicine: Lessons learned from implementation of a pharmacogenetics-based patient care program in a real-world setting. Clin Pharmacol Therapeutics 106(5):933–935. https://doi.org/10.1002/cpt.1611
doi: 10.1002/cpt.1611
Lee YM, McKillip RP, Borden BA, Klammer CE, Ratain MJ, O’Donnell PH (2017) Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation. Pharmacogenet Genomics 27(5):179–189. https://doi.org/10.1097/fpc.0000000000000275
doi: 10.1097/fpc.0000000000000275
pubmed: 28267054
pmcid: 5478379
Lemke AA, Hulick PJ, Wake DT, Wang C, Sereika AW, Yu KD, ... Dunnenberger HM (2018) Patient perspectives following pharmacogenomics results disclosure in an integrated health system. Pharmacogenomics 19(4):321–331. https://doi.org/10.2217/pgs-2017-0191
Liko I, Lai E, Griffin RJ, Aquilante CL, Lee YM (2020) Patients’ perspectives on psychiatric pharmacogenetic testing. Pharmacopsychiatry 53(6):256–261. https://doi.org/10.1055/a-1183-5029
doi: 10.1055/a-1183-5029
pubmed: 32583391
Linde K, Kriston L, Rücker G, Jamil S, Schumann I, Meissner K, ... Schneider A (2015) Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Ann Fam Med 13(1):69–79. https://doi.org/10.1370/afm.1687
Lomas J (1993) Diffusion, dissemination, and implementation: who should do what? Ann N Y Acad Sci 703:226–235. https://doi.org/10.1111/j.1749-6632.1993.tb26351.x . (discussion 235–227)
doi: 10.1111/j.1749-6632.1993.tb26351.x
pubmed: 8192299
Madadi P, Joly Y, Avard D, Chitayat DC, Smith MA, Ross CJD, ... Koren G (2010) Communicating pharmacogenetic research results to breastfeeding mothers taking codeine: A pilot study of perceptions and benefits. Clin Pharmacol Therapeutics 88(6):792–795. https://doi.org/10.1038/clpt.2010.125
Mark TL, Levit KR, Buck JA (2009) Datapoints: Psychotropic drug prescriptions by medical specialty. Psychiatr Serv 60(9):1167–1167. https://doi.org/10.1176/ps.2009.60.9.1167
doi: 10.1176/ps.2009.60.9.1167
pubmed: 19723729
McInnes G, Lavertu A, Sangkuhl K, Klein TE, Whirl-Carrillo M, Altman RB (2021) Pharmacogenetics at scale: An analysis of the UK Biobank. Clin Pharmacol Therapeutics 109(6):1528–1537. https://doi.org/10.1002/cpt.2122
doi: 10.1002/cpt.2122
Meyer UA (2004) Pharmacogenetics – five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 5(9):669–676. https://doi.org/10.1038/nrg1428
doi: 10.1038/nrg1428
pubmed: 15372089
Motulsky AG (1957) Drug reactions, enzymes, and biochemical genetics. J Am Med Assoc 165(7):835–837. https://doi.org/10.1001/jama.1957.72980250010016
doi: 10.1001/jama.1957.72980250010016
pubmed: 13462859
Mukerjee G, Huston A, Kabakchiev B, Piquette-Miller M, van Schaik R, Dorfman R (2018) User considerations in assessing pharmacogenomic tests and their clinical support tools. Genomic Med 3(1):26. https://doi.org/10.1038/s41525-018-0065-4
doi: 10.1038/s41525-018-0065-4
NICE (2022) NICE health technology evaluations: the manual. https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation . Accessed Jan 2024
O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA (2014) Standards for reporting qualitative research: a synthesis of recommendations. Academic Medicine 89(9). https://journals.lww.com/academicmedicine/Fulltext/2014/09000/Standards_for_Reporting_Qualitative_Research__A.21.aspx
O'Connor EA, Whitlock EP, Gaynes B, Beil TL (2009) U.S. preventive services task force evidence syntheses, formerly systematic evidence reviews. In Screening for depression in adults and older adults in primary care: an updated systematic review. Agency for Healthcare Research and Quality (US)
Ontario Health (2021) Multi-gene pharmacogenomic testing that includes decision-support tools to guide medication selection for major depression: a health technology assessment (Ontario Technology Assessment Series, Issue. https://www.hqontario.ca/evidence-to-improve-care/health-technology-assessment/reviews-and-recommendations/multi-gene-pharmacogenomic-testing-that-includes-decision-support-tools-to-guide-medication-selection-for-major-depression . Accessed Jan 2024
Ontario Health (2023) Health technology assessments methods and process guide. https://www.hqontario.ca/Portals/0/documents/evidence/reports/hta-methods-and-process-guide-en.pdf . Accessed Jan 2024
Oslin DW, Lynch KG, Shih M-C, Ingram EP, Wray LO, Chapman SR, ... Group PCR (2022) Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: The PRIME Care Randomized Clinical Trial. JAMA 328(2): 151-161 https://doi.org/10.1001/jama.2022.9805
Papastergiou J, Quilty LC, Li W, Thiruchselvam T, Jain E, Gove P, ... Pojskic N (2020) Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial. Clin Transl Sci 14(4): 1359–1368. https://doi.org/10.1111/cts.12986
PharmGKB (2022) PharmGKB. https://www.pharmgkb.org/ . Accessed Jan 2024
QRS International (2022) NVivo. https://www.qsrinternational.com/nvivo-qualitative-data-analysis-software/home
Rigter T, Jansen ME, de Groot JM, Janssen SWJ, Rodenburg W, Cornel MC (2020) Implementation of pharmacogenetics in primary care: A multi-stakeholder perspective. Front Genet 11:10. https://doi.org/10.3389/fgene.2020.00010
doi: 10.3389/fgene.2020.00010
pubmed: 32076434
pmcid: 7006602
Rogers EM (2003) Diffusion of Innovations, 5th Edition. Free Press. https://books.google.ca/books?id=9U1K5LjUOwEC
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, ... Fava M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry 163(11): 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905
Sandelowski M (2000) Whatever happened to qualitative description? Res Nurs Health 23(4):334–340. https://doi.org/10.1002/1098-240x(200008)23:4%3c334::aid-nur9%3e3.0.co;2-g
doi: 10.1002/1098-240x(200008)23:4<334::aid-nur9>3.0.co;2-g
pubmed: 10940958
Shaw JL, Robinson R, Starks H, Burke W, Dillard DA (2013) Risk, reward, and the double-edged sword: perspectives on pharmacogenetic research and clinical testing among Alaska Native people. Am J Public Health 103(12):2220–2225. https://doi.org/10.2105/ajph.2013.301596
doi: 10.2105/ajph.2013.301596
pubmed: 24134351
pmcid: 3828986
Slomp C, Morris E, Edwards L, Hoens AM, Landry G, Riches L, ... Austin J (2022) Pharmacogenomic testing for major depression: A qualitative study of the perceptions of people with lived experience and professional stakeholders. Can J Psychiatry. https://doi.org/10.1177/07067437221140383
Statistics Canada (2021a) Table 98–10–0020–01: age (in single years), average age and median age and gender: Canada, provinces and territories, census metropolitan areas and census agglomerations with parts. https://doi.org/10.25318/9810002001-eng . Accessed Jan 2024
Statistics Canada (2021b) Table 98–10–0351–01: visible minority by gender and age: Canada, provinces and territories. https://doi.org/10.25318/9810035101-eng . Accessed Jan 2024
Statistics Canada (2021c) Table 98–10–0481–01: place of work status by highest level of education and gender: Canada, provinces and territories, census divisions and census subdivisions. https://doi.org/10.25318/9810048101-eng . Accessed Jan 2024
Subasri M, Barrett D, Sibalija J, Bitacola L, Kim RB (2021) Pharmacogenomic-based personalized medicine: Multistakeholder perspectives on implementational drivers and barriers in the Canadian healthcare system. Clin Transl Sci 14(6):2231–2241. https://doi.org/10.1111/cts.13083
doi: 10.1111/cts.13083
pubmed: 34080317
pmcid: 8604218
Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, ... Guchelaar HJ (2023) A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet 401(10374): 347–356. https://doi.org/10.1016/s0140-6736(22)01841-4
Trinidad SB, Coffin TB, Fullerton SM, Ralston J, Jarvik GP, Larson EB (2015) “Getting off the Bus Closer to Your Destination”: Patients’ views about pharmacogenetic testing. Perm J 19(3):21–27. https://doi.org/10.7812/tpp/15-046
doi: 10.7812/tpp/15-046
pubmed: 26057686
pmcid: 4500477
Vanstone M, King C, de Vrijer B, Nisker J (2014) Non-invasive prenatal testing: ethics and policy considerations. J Obstet Gynaecol Can 36(6):515–526. https://doi.org/10.1016/S1701-2163(15)30568-5
doi: 10.1016/S1701-2163(15)30568-5
pubmed: 24927192
Vanstone M, Yacoub K, Giacomini M, Hulan D, McDonald S (2015) Women’s experiences of publicly funded non-invasive prenatal testing in Ontario, Canada: Considerations for health technology policy-making. Qual Health Res 25(8):1069–1084. https://doi.org/10.1177/1049732315589745
doi: 10.1177/1049732315589745
pubmed: 26063605
Vanstone M, Cernat A, Majid U, Trivedi F, De Freitas C (2019) Perspectives of pregnant people and clinicians on noninvasive prenatal testing: A systematic review and qualitative meta-synthesis. Ont Health Technol Assess Ser 19(5):1–38
pubmed: 30838086
pmcid: 6398533